Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2025 Filed Feb 27, 2025 22:37 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 57,635 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005878 · form4-02272025_100208.xml · derivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,635 Underlying: Common Shares · 57,635 shares Expires 2035-02-24 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,211 on February 25, 2026, 19,212 on February 25, 2027, and 19,212 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:37 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 15,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005878 · form4-02272025_100208.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,281 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:58 UTC |
Earnhardt Lisa DEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 69,977 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005886 · form4-02272025_100253.xml · derivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,977 Underlying: Common Shares · 69,977 shares Expires 2035-02-24 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,325 on February 25, 2026, 23,326 on February 25, 2027, and 23,326 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:58 UTC |
Earnhardt Lisa DEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 18,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005886 · form4-02272025_100253.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,250 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:07 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
GrantOption (right to buy) · Derivative | 241,706 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005891 · form4-02272025_110246.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,706 Underlying: Common Shares · 241,706 shares Expires 2035-02-24 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 80,568 on February 25, 2026, 80,569 on February 25, 2027, and 80,569 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:07 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
GrantCommon shares without par value | 64,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005891 · form4-02272025_110246.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,956 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:17 UTC |
MCCOY JOHN A. JR.VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 15,040 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005894 · form4-02272025_110224.xml · derivative · entry 3 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,040 Underlying: Common Shares · 15,040 shares Expires 2035-02-24 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,013 on February 25, 2026, 5,013 on February 25, 2027, and 5,014 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:17 UTC |
MCCOY JOHN A. JR.VICE PRESIDENT
|
GrantCommon shares without par value | 4,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005894 · form4-02272025_110224.xml · nonDerivative · entry 1 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,719 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:35 UTC |
Morrone Louis H.EXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 38,108 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005900 · form4-02272025_110234.xml · derivative · entry 3 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,108 Underlying: Common Shares · 38,108 shares Expires 2035-02-24 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,702 on February 25, 2026, 12,703 on February 25, 2027, and 12,703 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:35 UTC |
Morrone Louis H.EXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 10,232 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005900 · form4-02272025_110234.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,375 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:26 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 39,896 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005897 · form4-02272025_110242.xml · derivative · entry 3 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,896 Underlying: Common Shares · 39,896 shares Expires 2035-02-24 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,298 on February 25, 2026, 13,299 on February 25, 2027, and 13,299 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:26 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 10,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005897 · form4-02272025_110242.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,972 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:47 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 61,580 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005918 · form4-02272025_110246.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,580 Underlying: Common Shares · 61,580 shares Expires 2035-02-24 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,526 on February 25, 2026, 20,527 on February 25, 2027, and 20,527 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:47 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 16,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005918 · form4-02272025_110246.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,231 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:56 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 45,730 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005920 · form4-02272025_110232.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,730 Underlying: Common Shares · 45,730 shares Expires 2035-02-24 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,243 on February 25, 2026, 15,243 on February 25, 2027, and 15,244 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:56 UTC |
Wainer Andrea FEXECUTIVE VICE PRESIDENT
|
GrantCommon shares without par value | 12,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005920 · form4-02272025_110232.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,643 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 22:51 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
Exercise / conversionOption (right to buy) · Derivative | 285,388 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-25-003394 · form4-02072025_100204.xml · derivative · entry 4 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 285,388 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 22:51 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
SaleCommon shares without par value | 285,388 | $131.17 | $37,435,200.12 |
DisclosureSEC source: 0001415889-25-003394 · form4-02072025_100204.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,059 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.68 to $131.38, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 22:51 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
Exercise / conversionCommon shares without par value | 285,388 | $38.40 | $10,958,899.20 |
DisclosureSEC source: 0001415889-25-003394 · form4-02072025_100204.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 505,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 00:08 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 23,771 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-25-002584 · form4-02012025_120236.xml · derivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 23,771 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 00:08 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 23,771 | $128.50 | $3,054,573.50 |
DisclosureSEC source: 0001415889-25-002584 · form4-02012025_120236.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,697 Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 00:08 UTC |
Salvadori Daniel Gesua SiveEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 23,771 | $38.40 | $912,806.40 |
DisclosureSEC source: 0001415889-25-002584 · form4-02012025_120236.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 00:16 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 58,428 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-25-002589 · form4-02012025_120221.xml · derivative · entry 6 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 58,428 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 00:16 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 58,428 | $128.07 | $7,482,628.56 |
DisclosureSEC source: 0001415889-25-002589 · form4-02012025_120221.xml · nonDerivative · entry 4 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,806 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.00 to $128.40, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 00:16 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 58,428 | $38.40 | $2,243,635.20 |
DisclosureSEC source: 0001415889-25-002589 · form4-02012025_120221.xml · nonDerivative · entry 3 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2025 Filed Feb 1, 2025 00:16 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 131,360 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-25-002589 · form4-02012025_120221.xml · derivative · entry 5 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,428 Underlying: Common shares · 131,360 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 29, 2025 Filed Feb 1, 2025 00:16 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 131,360 | $128.35 | $16,859,675.06 |
DisclosureSEC source: 0001415889-25-002589 · form4-02012025_120221.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,806 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.90 to $128.81, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 29, 2025 Filed Feb 1, 2025 00:16 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 131,360 | $38.40 | $5,044,224.00 |
DisclosureSEC source: 0001415889-25-002589 · form4-02012025_120221.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2025 Filed Jan 31, 2025 00:33 UTC |
Morrone Louis H.EXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 2,644 | $127.39 | $336,819.16 |
DisclosureSEC source: 0001415889-25-002423 · form4-01312025_120112.xml · nonDerivative · entry 1 Morrone Louis H. · CIK 0001867666 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Indirect · Profit Sharing Trust Disclosed balance after: 0 F1 · shares: Includes shares acquired pursuant to a dividend reinvestment feature. F2 · balance_after: Balance in the Abbott Laboratories Stock Retirement Trust as of January 29, 2025. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:02 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 69 | $113.11 | $7,804.59 |
DisclosureSEC source: 0001415889-25-000528 · form4-01032025_100102.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,988 Underlying: Common Shares · 69 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:07 UTC |
Gonzalez Patricia PaolaDirector
|
GrantStock Equivalent Units · Derivative | 291 | $113.11 | $32,915.01 |
DisclosureSEC source: 0001415889-25-000550 · form4-01032025_100122.xml · derivative · entry 1 Gonzalez Patricia Paola · CIK 0001879701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,125 Underlying: Common Shares · 291 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:26 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 324 | $113.11 | $36,647.64 |
DisclosureSEC source: 0001415889-25-000589 · form4-01032025_100149.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Shares · 324 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:19 UTC |
Roman Michael FDirector
|
GrantStock Equivalent Units · Derivative | 311 | $113.11 | $35,177.21 |
DisclosureSEC source: 0001415889-25-000575 · form4-01032025_100102.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,670 Underlying: Common Shares · 311 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 21:10 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 157,421 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025575 · form4-10232024_091049.xml · derivative · entry 5 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 157,421 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 21:10 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 150,271 | $116.98 | $17,578,701.58 |
DisclosureSEC source: 0001415889-24-025575 · form4-10232024_091049.xml · nonDerivative · entry 4 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,806 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.68 to $117.64, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 21:10 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 5,901 | $118.15 | $697,203.15 |
DisclosureSEC source: 0001415889-24-025575 · form4-10232024_091049.xml · nonDerivative · entry 3 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 335,077 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.68 to $118.59, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 21:10 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 1,249 | $118.81 | $148,393.69 |
DisclosureSEC source: 0001415889-24-025575 · form4-10232024_091049.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 340,978 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.68 to $118.92, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 21:10 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 157,421 | $47.00 | $7,398,787.00 |
DisclosureSEC source: 0001415889-24-025575 · form4-10232024_091049.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 342,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:27 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 69 | $114.01 | $7,866.69 |
DisclosureSEC source: 0001415889-24-024236 · form4-10012024_091011.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,872 Underlying: Common Shares · 69 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:33 UTC |
Gonzalez Patricia PaolaDirector
|
GrantStock Equivalent Units · Derivative | 289 | $114.01 | $32,948.89 |
DisclosureSEC source: 0001415889-24-024238 · form4-10012024_091038.xml · derivative · entry 1 Gonzalez Patricia Paola · CIK 0001879701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,815 Underlying: Common Shares · 289 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:39 UTC |
Roman Michael FDirector
|
GrantStock Equivalent Units · Derivative | 309 | $114.01 | $35,229.09 |
DisclosureSEC source: 0001415889-24-024240 · form4-10012024_091021.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,338 Underlying: Common Shares · 309 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:48 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 322 | $114.01 | $36,711.22 |
DisclosureSEC source: 0001415889-24-024241 · form4-10012024_091053.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,271 Underlying: Common Shares · 322 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:24 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
Exercise / conversionOption (right to buy) · Derivative | 14,243 | $0.00 Strike: $48.90 | $0.00 |
DisclosureSEC source: 0001415889-24-023389 · form4-09132024_090935.xml · derivative · entry 7 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 14,243 shares Expires 2025-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:24 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
Exercise / conversionOption (right to buy) · Derivative | 127,436 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023389 · form4-09132024_090935.xml · derivative · entry 6 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 127,436 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:24 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
SaleCommon shares without par value | 61,380 | $116.90 | $7,175,322.00 |
DisclosureSEC source: 0001415889-24-023389 · form4-09132024_090935.xml · nonDerivative · entry 4 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,059 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.58 to $117.29, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:24 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
SaleCommon shares without par value | 80,299 | $116.04 | $9,317,895.96 |
DisclosureSEC source: 0001415889-24-023389 · form4-09132024_090935.xml · nonDerivative · entry 3 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,439 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.58 to $116.54, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:24 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
Exercise / conversionCommon shares without par value | 14,243 | $48.90 | $696,482.70 |
DisclosureSEC source: 0001415889-24-023389 · form4-09132024_090935.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:24 UTC |
Ford Robert BDirector · CHAIRMAN AND CEO
|
Exercise / conversionCommon shares without par value | 127,436 | $47.00 | $5,989,492.00 |
DisclosureSEC source: 0001415889-24-023389 · form4-09132024_090935.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2024 Filed Sep 4, 2024 23:52 UTC |
MCCOY JOHN A. JR.VICE PRESIDENT
|
SaleCommon shares without par value | 27 | $114.83 | $3,100.41 |
DisclosureSEC source: 0001415889-24-022826 · form4-09042024_100931.xml · nonDerivative · entry 2 MCCOY JOHN A. JR. · CIK 0001644207 · VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,681 Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:03 UTC |
Boudreau Philip PEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 387 | $113.27 | $43,835.49 |
DisclosureSEC source: 0001415889-24-022823 · form4-09042024_100951.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,966 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.